Physician profile
Duane Keitel
NPI 1487644803
$104,913.48
in general payments reported to CMS, 2019-2025
33 companies · $21K in 2025
The $21K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,015 · 2021: $12K · 2022: $14K · 2023: $13K · 2024: $24K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $9,675 · Consulting Fee: $2,766 · Travel and Lodging: $1,029 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,225.00 |
| Food and Beverage | $9,674.70 |
| Consulting Fee | $2,766.00 |
| Travel and Lodging | $1,028.65 |
| Education | $256.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $87,874.18 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $6,464.62 | 2019-2025 | |
| Amgen INC. | $2,120.90 | 2022-2025 | Tezspire |
| Glaxosmithkline, LLC. | $1,857.34 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $1,191.18 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $947.15 | 2019-2025 | Dupixent |
| Pfizer INC. | $859.39 | 2019-2025 | |
| Csl Behring | $490.31 | 2019-2025 | Haegarda, Andembry, Kcentra |
| Novartis Pharmaceuticals Corporation | $481.70 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $464.55 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $385.20 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $256.79 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $194.98 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $194.72 | 2019-2022 | |
| Covis Pharma Gmbh | $180.75 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $151.08 | 2020-2025 | Eohilia, Takhzyro |
| Lilly USA, LLC | $118.81 | 2025 | Ebglyss |
| Optinose US, INC. | $104.14 | 2019-2023 | |
| Grifols USA, LLC | $101.79 | 2020-2021 | |
| Abbvie INC. | $100.43 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $100.10 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $54.76 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $29.07 | 2021 | |
| Pharming Healthcare, INC. | $25.85 | 2019 | |
| Organon LLC | $21.57 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.07 | 2020 | |
| Biocryst Pharmaceuticals, INC. | $19.71 | 2020 | |
| Hikma Pharmaceuticals USA | $19.21 | 2022 | |
| Shire North American Group INC | $18.55 | 2019 | |
| Leo Pharma INC. | $16.76 | 2023 | Adbry |
| Phadia US INC. | $16.40 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.37 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.05 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Keitel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.